Importance of serotonergic mechanisms in the thrombotic complications in hemodialyzed patients treated with erythropoietin

Nephron

Volumn 84, Issue 4, 2000, Pages 305-311

  Małyszko, Jacek S ^a   Małyszko, Jolanta ^a   Pawlak, Krystyna ^a   Pawlak, Dariusz ^a   Buczko, Włodzimierz ^a   Myśliwiec, Michał ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Endothelium; Erythropoietin; Factor VII; Serotonin; Thrombomodulin; Tissue factor; Tissue factor pathway inhibitor; Von Willebrand factor

Indexed keywords

BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7; LIPOPROTEIN A; RECOMBINANT ERYTHROPOIETIN; SEROTONIN; THROMBOMODULIN; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; VITRONECTIN; VON WILLEBRAND FACTOR;

ADULT; AGED; ANEMIA; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; FEMALE; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEROTONIN BLOOD LEVEL; SEROTONINERGIC SYSTEM; THROMBOEMBOLISM; UREMIA; VASCULAR ENDOTHELIUM;

EID: 0034111121     PISSN: 00282766     EISSN: None     Source Type: Journal    
DOI: 10.1159/000045604     Document Type: Article

References (38)

1. Eberst E, Berkowitz LR: Hemostasis in renal disease: Pathophysiology and management. Am J Med 1994;96:168-179.
2. Locatelli F, Del Vecchio L, Manzoni C: Morbidity and mortality on maintenance hemodialysis. Nephron 1998;80:380-400.
3. Bombeli T, Mueller M, Haeberli A: Anticoagulant properties of the vascular endothelium. Thromb Haemost 1997;77:408-421.
4. Wirtz JJM, van Esser JWJ, Hamulyak K, Leunissen KLM, van Hoof JP: The effects of recombinant human erythropoietin on hemostasis and fibrinolysis in hemodialysis patients. Clin Nephrol 1992;38:277-282.
5. Huraib S, Al-Momen AK, Gader AMA, Mitwalli A, Sulimani F, Abu-Aisha H: Effect of recombinant human erythropoietin on the hemostatic system in chronic hemodialysis patients. Clin Nephrol 1991;36:252-257.
6. Takayama K: Changes in endothelial vasoactive substances and blood coagulation and fibrinolysis functions under recombinant human erythropoietin therapy in hemodialysis patients. Jpn J Nephrol 1993;35:197-188.
7. Malyszko J, Malyszko JS, Borawski J, Rydzewski A, Kalinowski M, Azzadin A, Mysliwiec M, Buczko W: A study of platelet function, some hemostatic and fibrinolytic paramters in relation to serotonin in hemodialyzed patients under erythropoietin therapy. Thromb Res 1995;77:133-144.
8. Van Zwieten PA: Pathophysiological relevance of serotonin. J Cardiovasc Pharmacol 1987; 10(suppl 3):19-25.
9. De Clerck F, van Nueten JM, Reneman RS: Platelet-vessel wall interactions: Implications of 5-hydroxytryptamine. A review. Agents Actions 1984;15:612-626.
10. Malyszko J, Malyszko JS, Pawlak K, Mysliwiec M: Coagulolytic system and endothelial function in cyclosporine-treated kidney alograft recipients. Transplantation 1996;62:828-830.
11. Nakayama M, Yamada K, Yamamoto Y, Yokoyama K, Nakano H, Kubo H, Shigematsu T, Kawaguchi Y, Sakai O: Vascular dysfunction in patients on regular dialysis treatment. Clin Nephrol 1994;42:177-120.
12. Malyszko J, Malyszko JS, Pawlak D, Pawlak K, Buczko W, Mysliwiec M: Platelet function, hemostasis and serotonin in acute and chronic renal failure. Thromb Res 1996;83:351.
13. Willerson JT: Serotonin and thrombotic complications. J Cardiovasc Pharmacol 1991; 17(suppl 5):513-520.
14. Malyszko J, Urano T, Knofler R, Taminato A, Yoshimi T, Takada Y, Takada A: Daily variations of platelet aggregation in relation to blood and plasma serotonin in diabetes. Thromb Res 1994;75:569-576.
15. Picard M, Olichon D, Gombert J: Determination of serotonin in plasma by liquid chromatography with electrochemical detection. J Chromatogr 1985;341:445-451.
16. Pawlak D, Malyszko J, Malyszko JS, Pawlak K, Buczko W, Mysliwiec M: Peripheral serotonergic system in uremia. Thromb Res 1996;83: 189-194.
17. Drummond A, Gordon J: Rapid sensitive microassay for platelet 5-HT. Thromb Diath Haemorrh (Stuttgart) 1974;31:366-367.
18. Koutouzov S, Cothenet-Vernoux L, Marche P, Dausse JP: Influence of alpha-and beta-adrenoreceptors on thrombin-induced serotonin release in rat platelets. Thromb Res 1985;40: 147-159.
19. Gordon GL, Olverman HJ: 5-Hydroxytryptamine and dopamine transport by rat and human blood platelets. Br J Pharmacol 1978;62: 219-226.
20. Cella G, Vertolli U, Naso A. Vianello A, Rampin E, Sharai A, Boeri G, Strauss WE: Tissue factor pathway inhibitor activity in uremic patients during hemodialysis. Thromb Res 1996; 81:671-677.
21. Kario K, Matsuo T, Yamada T, Matsuo M: Increased tissue factor pathway inhibitor levels in uremic patients on regular hemodialysis. Thromb Haemost 1994;71:275-279.
22. Kario K, Matsuo T, Matsuo M, Koide M, Yamada T, Nakamura S, Sakata T, Kato H, Miyata T: Marked increase of activated factor VII in uremic patients. Thromb Haemost 1995;73:763-767.
23. Broze GJ Jr: Tissue factor pathway inhibitor. Thromb Haemost 1995;74:90-93.
24. Koyama T, Nishida K, Ohdama S, Sawada M, Murakami N, Hirosawa S, Kuriyama R, Malsuzawa K, Hasegawa R, Aoki N: Determination of plasma tissue factor antigen and clinical significance. Br J Haematol 1994;87:343-347.
25. Fukuda C, Iijima K, Nakamura K: Measuring tissue factor (factor III) activity in plasma. Clin Chem 1989;35:1897-1900.
26. Sebekova K, Raucinova M, Dzurik R: Serotonin metabolism in patients with decreased renal function. Nephron 1989;53:229-232.
27. Eknoyan G, Brown CH: Biochemical abnormalities of platelets in renal failure. Am J Nephrol 1981;1:17-21.
28. Soslau G, Brodsky I, Putatunda B, Packer J, Schwartz AB: Selective reduction of serotonin storage and ATP release in chronic renal failure platelets. Am J Hematol 1990;35:171-176.
29. Boucek RJ, Alvarez TR: 5-Hydroxytryptamine: A cytospecific growth stimulator of cultured fibroblasts. Science 1970;167:898-899.
30. Aalto M, Kulonen M: Effects of serotonin, indomethacin and other antirheumatic drugs on the synthesis of collagen and other proteins in granulation tissue slices. Biochem Pharmacol 1972;21:2835-2840.
31. Rossi P, Zamboni L: Pulmonary atherosclerosis due to serotonin. Nature 1958;181:1216-1217.
32. Ahmed FS, Harrison CV: Morphological effects of serotonin on pulmonary arteries: An experimental study in rabbits. J Pathol Bacteriol 1964;87:3-5.
33. Hunt BJ, Segal H, Yacoub M: Hemostatic changes in heart transplant recipients and their relationship to accelerated coronary sclerosis. Transplantation 1993;55:309-314.
34. Preissner KT, Seiffert D: Role of vitronectin and its receptor in haemostasis and vascular remodeling. Thromb Res 1998;89:1-21.
35. Cotran RS, Pober JS: Effects of cytokines on vascular endothelium: Their role in vascular and immune injury. Kidney Int 1989;35:969-975.
36. Cotran RS, Pober JS: Cytokine-endothelial interaction in inflammation, immunity and vascular injury. J Am Soc Nephrol 1990;1:225-235.
37. Bagdade JD: Chronic renal failure and atherogenesis. Serum factors stimulate the proliferation of human arterial smooth muscle cells. Atherosclerosis 1979;34:243-248.
38. Strutz F, Muller GA: On the progression of chronic renal disease. Nephron 1995;69:371-379.